UK experts back routine MenB vaccine at 15 after 2026 outbreaks, but ministers still have the final say
Britain’s vaccine advisers have recommended a new routine meningococcal B vaccination offer for teenagers at around age 15, a significant shift that follows the Kent outbreak earlier in 2026 but still stops short of an immediate policy change.
The Joint Committee on Vaccination and Immunisation, or JCVI, said on July 16, 2026, that the government should consider a routine adolescent MenB programme for people who were vaccinated in infancy after the NHS added MenB to the childhood schedule in 2015. The Department of Health and Social Care now has to decide whether to turn that recommendation into policy.
That distinction matters. Families looking at the latest headlines are not seeing a new national rollout begin this week. What changed on Thursday is the expert recommendation behind a possible future schedule, alongside a stronger case for catch-up protection in older teenagers who missed infant vaccination.
What JCVI actually recommended
JCVI said adolescents born on or after May 1, 2015, who were eligible for MenB vaccination in infancy, should be offered a routine dose of 4CMenB at around age 15. Because that infant programme began in 2015, the first cohort affected by the proposed routine offer would turn 15 in 2030.
The committee also said ministers should strongly consider a two-dose offer for adolescents born on or before April 30, 2015, plus catch-up protection for groups who could otherwise fall between the current one-off 2026 offer and any later routine programme.
In practical terms, the advisory body is trying to close a protection gap. Younger children who entered the infant schedule already have a vaccination history JCVI can build on. Older teenagers, including many now heading toward university, do not.
| Programme | Who it covers | Dose plan | Status on July 16, 2026 |
|---|---|---|---|
| One-off 2026 MenB offer | Eligible young people, including first-time university entrants and some residential students | Two doses at least 4 weeks apart | Officially announced and live, with first doses from July 20, 2026 |
| Proposed routine adolescent programme | Teenagers around age 15 who were eligible for infant MenB vaccination | One dose of 4CMenB for primed adolescents | Recommended by JCVI, awaiting government decision |
| Additional catch-up approach | Older or in-between cohorts not covered cleanly by the two lanes above | Two doses | Strongly supported by JCVI on equity grounds |
Why the advice changed now
The government asked JCVI to review adolescent MenB vaccination after the Kent outbreak in March 2026. In its statement, the committee said new evidence helped it revisit a question that had previously looked difficult on cost-effectiveness grounds.
That updated picture includes evidence on how a single adolescent dose may work in people who were vaccinated as infants, alongside fresh analysis of outbreak risk and the broader burden of meningococcal disease. JCVI also said it reviewed evidence around possible protection against gonococcal infection, though the core recommendation remains focused on invasive meningococcal disease.
For readers who have followed Archyde’s earlier coverage of the current student programme, including the urgent MenB vaccination timeline for eligible teens and under-25 students, Thursday’s development is better understood as the next policy layer rather than a replacement for the one-off campaign already underway.
What families and students should watch next
The most immediate public-health message has not changed: people who already qualify for the temporary 2026 offer should not wait for a broader policy fight to play out. UKHSA’s June guidance says first doses begin on July 20, 2026, and two doses are needed for protection.
That is especially relevant for students preparing to move into shared housing or university accommodation in the autumn, where close contact increases the chance of meningococcal bacteria spreading. It also helps explain why campaigners have pressed for clearer access after earlier cases drew national attention, a debate Archyde reflected in its report on a mother’s plea after her son’s critical illness.
What ministers decide next will shape the longer-term answer. If the government accepts JCVI’s central recommendation, the UK would move toward a standing adolescent MenB offer linked to the post-2015 infant cohorts. If it goes further and funds the broader catch-up approach, it would narrow the gap for teenagers who missed infant doses entirely.
For now, the policy direction is clearer than the implementation calendar. The committee has given ministers a roadmap; the next question is how much of it they are willing to fund, and how quickly they want protection to reach the teenagers still exposed between the old system and the new one advisers now want in place.
